Publications

Purpose  Outcomes in Randomized Controlled Trials (RCT) are often computed as changes from baseline of finite scales (e.g., pain assessments going from 0 to 10). When subjects receive effective treatment over time they may reach the limit of a finite scale. In that case, the score limitation at the bottom of the finite scale, called

Scientific Poster presented on October 2021 at the Annual Meeting of the Royal Statistical Society of Belgium. The amount of data collected from patients involved in clinical trials is continuouslygrowing. All baseline patient characteristics are potential covariates that could be used to improve clinical trial analysis and power. However, the limited number of patients in phases

Scientific Poster presented on September 2021 at the International Society for CNS Clinical Trial and Methodology Conference The Methodological Question Being Addressed  Recently, several models predictive of the placebo response in pain RCTs have been published. The most obvious application of these models is the identification and exclusion of placebo responders before randomization in an enriched screening procedure. We investigated the benefit

The magnitude and the variability of the placebo response have a confounding influence when testing the superiority of active compounds compared to placebo. Identifying covariates associated with this PD placebo response may help mitigate its effect, increase the study power, and result in more optimal RCT design in future studies.